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Toxoplasma gondii has a clonal population genetic structure with three (I, II, and III) lineages that predominate
in North America and Europe. Type II strains cause most cases of symptomatic human infections in France and the
United States, although few other regions have been adequately sampled. Here we determined the parasite genotype
in amniotic fluid and cerebrospinal fluid samples from congenital toxoplasmosis cases in Poland. Nineteen con-
firmed congenital cases of toxoplasmosis were analyzed, including both severe and asymptomatic cases. The
genotype of parasite strains causing congenital infection was determined by direct PCR amplification and restric-
tion fragment length polymorphism analysis. Nested multiplex PCR analysis was used to type four independent
polymorphic markers. The sensitivity of multiplex nested PCR was>25 parasites/ml in amniotic fluid and cerebral
spinal fluid samples. Parasite DNA was successfully amplified in 9 of 19 samples (eight severely affected and one
asymptomatic fetus). Only genotype II parasites were identified as the source of T. gondii infection based on
restriction fragment length polymorphism analysis. Strains causing congenital infections were also typed indirectly
based on detection of antibodies to strain-specific peptides. Serotyping indicated that 12 of 15 cases tested were
caused by type II strains and these positives included both symptomatic and asymptomatic infections. Overall, the
combined analysis indicated that 14 of the cases were caused by type II strains. Our results are consistent with the
hypothesis that parasite burden is associated with severity of congenital toxoplasmosis and indicate that serological
testing provides a promising method for genotypic analysis of toxoplasmosis.
Toxoplasmosis is a common parasitic disease caused by the
protozoan parasite Toxoplasma gondii. Seroprevalence varies
between different geographic regions: in Poland, 2,200 (41.3%)
out of 4,916 pregnant women were found to have T. gondii-
specific anti-immunoglobulin G (IgG) antibodies (20, 20a).
Infection can be acquired by ingestion of viable tissue cysts in
undercooked meat or oocysts excreted by cats (23). T. gondii is
a major cause of morbidity and mortality in congenitally in-
fected infants and immunodeficient and immunocompromised
patients (15).
The population genetic structure of T. gondii is highly clonal,
despite a sexual phase in the life cycle (14, 25, 26). Three
predominant clonal types (I, II, and III) are recently derived
from recombination between two highly similar ancestral line-
ages (8, 27). Recombinant genotypes are rarely found in na-
ture, indicating infrequent sexual recombination between the
three lineages (1, 14). Type II strains have been identified as
the cause of more than 70% of human cases of toxoplasmosis
in the United States and France (1, 5, 14). Type II strains are
relatively avirulent in mice yet they readily establish chronic
infections characterized by tissue cysts that are highly infec-
tious by the oral route (25, 27). Type I strains are more virulent
in mice and have a greater capacity to cross tissue barriers in
vitro and in vivo (2, 26, 28).
Enhanced migration could potentially lead to greater capac-
ity to cause congenital infection due to transplacental trans-
mission, although such a relationship has not been directly
demonstrated. A single study from Spain indicated that strains
possessing the type I allele at the SAG2 locus were found in 6
of 13 cases of congenital infection (6). However, even strains
that are nonvirulent in the mouse model are capable of causing
severe disease in humans, as shown by the prevalence of type
II strains in congenital toxoplasmosis in France (1).
While the majority of genotyping studies have been based on
polymorphic DNA markers, one of the primary limitations of
this method is the inability to type strains causing chronic
infection. Strains of T. gondii are highly similar antigenically;
however, the recent identification of serological epitopes that
are strain specific raises the possibility of genotyping even
chronic infections based on serological profile (17). Serological
typing based on strain-specific peptides is capable of distin-
guishing type II strains from non-type II (typically I or III)
* Corresponding author. Mailing address: Department of Molecular
Microbiology, Washington University School of Medicine, 660 S.
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strains and offers the promise for determining the frequency of
strain types that cause both acute and chronic infections.
The presentation of congenital toxoplasmosis varies widely
from subclinical to severe cases, which may cause fetal or
neonatal death (23). The frequency and severity of fetal toxo-
plasmosis depends on the time when infection takes place
during pregnancy. Early in pregnancy, infections are less likely
to cross the placental barrier, yet those congenital infections
that do result are more severe. While infection occurs more
readily late in pregnancy, the majority of such cases are mild or
asymptomatic at birth (summarized in reference 23). High
parasite concentrations in the amniotic fluid (AF) have been
associated with severe outcome (24).
In the present study we examined a set of well-characterized
cases of congenital toxoplasmosis from Poland. We deter-
mined the genotypes of T. gondii found in AF and cerebral
spinal fluid (CSF) from cases of congenital toxoplasmosis using
a newly developed multiplex nested-PCR typing system (16).
We also analyzed serological responses to strain-specific pep-
tides in order to serotype infections (17).
MATERIALS AND METHODS
Clinical cases of congenital toxoplasmosis. Nineteen cases of congenital toxo-
plasmosis diagnosed at the Research Institute Polish Mother’s Memorial Hospital
(RIPMMH, Lodz, Poland) between March 1999 and June 2003 were included in the
study. The following classification of clinical forms of congenital toxoplasmosis was
used. Symptomatic toxoplasmosis was described when ventricular dilatation was
observed in repeated ultrasound scans and/or fetal and neonatal death was reported.
Chorioretinitis was diagnosed during the neonatal period. Fetuses and/or neo-
nates that did not present pathological symptoms were classified as asymptom-
atic. After birth, a team of specialists including neurologists and ophthalmolo-
gists attended symptomatic and asymptomatic neonates. Congenitally infected
infants were treated with combined therapy with pyrimethamine and sulfadia-
zine. The studies were conducted with approval of the Ethical Committee of
RIPMMH, Lodz
Confirmation of congenital infection. Serological testing (anti-Toxoplasma
IgG, IgM, IgA, and IgG avidity) was performed in the Department of Microbi-
ology, RIPMMH, Lodz (20a). Prior to March 2000, screening of maternal sera
for Toxoplasma-specific IgG antibodies was performed with a latex agglutination
kit (Toxo Screen DA; bioMe´rieux) (positive cutoff: 4 IU/ml), or an indirect
agglutination assay (Platelia Toxo-G; Diagnostics Sanofi Pasteur) (positive cut-
off: 6 IU). Testing for Toxoplasma-specific IgM was conducted using an en-
zyme-linked immunosorbent assay (ELISA) (Platelia Toxo M; Diagnostics
Sanofi Pateur). (cutoffs: 0 to 1 IU/ml, negative; 1 to 2 IU/ml, borderline; 2
IU/ml, positive). In cases where specific IgM was detected, an immunosorbent
agglutination assay was used for detecting specific IgM and IgA (bioMe´rieux)
(cutoffs: 6, negative; 6 to 7, borderline; 7, positive). In neonates, the Platelia
Toxo-M and Toxo-A tests were used with the same cutoff values as in the
mothers and the immunosorbent agglutination assay was used for IgM and IgA
(cutoffs: 3, negative; 3 to 6, intermediate; 6, positive). IgG avidity was tested
using an ELISA (Labsystems) (cutoffs: low, 15%; borderline, 15 to 30%; high,
30%).
Beginning in March 2000, Toxoplasma-specific IgG was detected in sera from
mothers and their neonates by enzyme-linked immunofluorescent assay (VIDAS
Toxo-IgG; bioMerieux) (positive cutoff: 8 IU/ml). Toxoplasma-specific IgM
was detected using VIDAS Toxo-IgM (bioMerieux) (positive cutoff: 0.65 IU/
ml) and Toxoplasma-specific IgA was detected using the Platelia Toxo-IgA
method as described above. IgG avidity was tested using the enzyme-linked
immunofluorescent assay test (VIDAS Toxo-avidity; bioMerieux) (cutoffs: low,
0.2; borderline, 0.2 to 0.3; high, 0.3).
PCR detection of parasite DNA was based on the B1 gene as described
previously (7). PCR assays and bioassay by inoculation of mice were conducted
in the Department of Medical Parasitology National Institute of Hygiene, War-
saw. For bioassay, 1 ml of AF or CSF was injected intraperitoneally into labo-
ratory mice (CFW/Pzh strain). Six weeks after inoculation, blood samples were
examined with the Toxo-Screen DA test to detect seroconversion and establish
the titer of Toxoplasma-specific IgG antibodies. The brains of these animals were
homogenized and inoculated into another pair of mice that were then examined
for Toxoplasma-specific antibodies as described above.
Clinical samples. AF samples were obtained by amniopuncture under sono-
graphic guidance in the Department of Ultrasound, RIPMMH, Lodz, Poland.
Additionally, in one case (number 18) fetal CSF was obtained when hydroceph-
alus was decompressed in utero by insertion of a ventriculoamniotic shunt (19).
In two cases (nos. 1 and 10), CSF samples were collected postnatally for geno-
typing. One neonate (no. 1) was confirmed infected by positive B1 PCR from
CSF taken a few days after birth (Table 1). In another case (no. 10), CSF was
available from the infant after long-term antiparasitic treatment. For three ne-
onates (nos. 16, 17, and 18), AF was not available and instead, neonatal blood
was used for typing. Negative controls consisted of AF or CSF samples from
pregnancies with negative anti-T. gondii serology after delivery. Samples were
collected and stored at 20°C at the Department of Fetal-Maternal Medicine
and Gynecology, Research Institute Polish Mother’s Memorial Hospital, Lodz,
Poland and then sent frozen on dry ice to the Department of Microbiology,
Washington University School of Medicine, Saint Louis, MO.
Experimental samples. T. gondii tachyzoites were cultivated by 2-day passage
in human foreskin fibroblast monolayers and purified from host cells as described
previously (14). Type strains consisted of RH (type I) (American Type Culture
Collection, Manassas, VA; ATCC 50174), PTG (type II) (ATCC 50841), and
CTG (type III) (ATCC 50842). T. gondii cells were harvested, counted, and
resuspended in phosphate-buffered saline (PBS). Two types of standards were
used for testing sensitivity. First, aliquots containing 1, 0.5, 2.5, 5, or 10 parasite
equivalents were made from a stock lysate of purified parasites prepared by
incubation with 100 g/ml proteinase K for 1 h at 37°C and 2 h at 50°C, followed
by heat inactivation at 90°C for 15 min. Second, aliquots (10 l) containing 5.0,
10.0, 25.0, 50.0, or 100.0 parasites were added to 1 ml of negative AF and
centrifuged at 3,000  g, and the pellet was used for analysis.
Multiplex PCR genotyping. We utilized a recently described multiplex nested
PCR for T. gondii genotyping based on four independent, unlinked markers:
5-SAG2, 3-SAG2, SAG3, GRA6, and BTUB (16). In the first round of PCR, all
reverse and forward external primers were combined in one reaction tube. The
PCR mixture consisted of 5 l of 10 PCR buffer (Sigma, St. Louis, MO)
containing 1.5 mM of MgCl2; 4 l of deoxynucleoside triphosphates (2.5 M
each) (Roche Applied Sciences, Indianapolis, IN); 0.15 l of 50 M of each
forward and reverse primer (Integrated DNA Technologies, Coralvile, IA); 0.5
l of (5 U/l) Taq DNA polymerase (Sigma); and 31.0 l of distilled, DNase-
and RNase-free water. PCR was conducted using a PTC-200 DNA engine system
Peltier thermal cycler (MJ Research Inc., Watertown, MA) programmed for
94°C for 30 seconds, 55°C for 60 seconds, and 72°C for 2 min during each of 35
cycles. PCR products were digested with restriction enzymes (New England
BioLabs, Inc., Beverley, MA) and restriction fragment length polymorphisms
(RFLPs) were visualized using ethidium bromide staining of 2% agarose gels.
Sample processing. Clinical samples of AF and CSF were centrifuged for 10 min
at 3,000  g and pellets were extracted with a QIAamp DNA blood minikit
(QIAGEN Inc., Valencia, CA). Neonatal whole blood (200 l) was processed
directly using the QIAamp DNA blood minikit. In the final step, samples were
eluted with 25 l of buffer. Multiplex PCR was conducted using 12.5 l of the eluted
samples as described above. Representative strains were used as positive controls.
Negative AF and CSF samples and distilled water served as negative controls.
Serological typing. Strain-specific polymorphic peptides derived from the T.
gondii dense granule (GRA) proteins GRA6 and GRA7 were coupled to keyhole
limpet hemocyanin as described previously (17). Within the abbreviated names
of the peptides, 6 denotes peptides from GRA6 and 7 those from GRA7; I/III or
II indicates the allele of the peptide, i.e., from which archetypal strain it was
derived; and indicates a truncated version of the diagnostic peptide. Coupled
peptides were diluted to 2 g/ml in 0.1 M carbonate buffer, pH 8.5, and 50 l of
each peptide solution was loaded into a polystyrene ELISA plate well overnight
at 4°C. Coated wells were blocked with 200 l of a 2% casein solution in PBS for
2 h at room temperature.
Sera were tested by adding 50 l of diluted human serum (typically 1:100) to
each well and incubating for 2 h at room temperature. ELISA plates were
washed four times with a PBS/0.1% Tween 20 solution before incubation with a
horseradish peroxidase-coupled monoclonal antibody against human IgG (BD
Pharmingen, San Diego, CA) for 1 h at room temperature. Plates were washed
in PBS and developed with 150 l of ABTS 2,2-azinobis(3-ethylbenzthiazoline-
sulfonic acid) (ABTS) reagents (Kirkegaard and Perry Laboratories, Inc., Gaithers-
burg, MD). Absorbance was read at 1, 2, and 4 h using a 405-nm filter. Two
control peptides served as negative controls to establish background reactivity for
normalization purposes. They consisted of a randomized sequence of the GRA6
peptide and a mix of peptides derived from the human and Leishmania EF1
proteins coupled to keyhole limpet hemocyanin.
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ELISA data for each infection serum were normalized by dividing the
optical density (OD) value obtained at each of the eight serotyping peptides
by the mean of the OD readings for the two control peptides. Negative
reactivity thus yields a theoretical value of 	1.0: values of 1.4 or greater are
considered significant positive reactivity against the serotyping peptides, as
defined previously (17). The four positive control sera utilized (two type II
and two type I/III) were from patients from whom parasites were recovered
and genotyped by PCR-RFLP.
TABLE 1. Clinical findings and genotype analysis in congenitally infected fetuses and infants with T. gondiia
Case
no.
Mother’s serology Symptomatic vs. asymptomaticcongenital toxoplasmosis Perinatal diagnosis Genotype Serotype
GW Anti-T. gondiiantibodies GW/NP Clinical findings
IUD,





1 34 IgG, IgM, IgA 35 Hydrocephaly Pos. Pos. IgG CSF II Mother II
IgG avidity low NP Chorioretinitis IgM Infant II
IgA
2 12 IgG, IgM Asymptomatic Pos. Pos. IgG AF II Mother Uncertain
31 IgG, IgM IgM Infant II
38 IgG, IgM, IgA IgA
3 27 IgG, IgM, IgA 29 Hydrocephaly IUD, 32 Pos. Pos. ND AF II Mother II
IgG avidity low Infant II
4 35 IgG, IgM, IgA 32 Hydrocephaly NP Pos. Pos. IgG AF II Mother II
IgG avidity low IgM Infant II
IgA
5 27 IgG, IgM, IgA 27 Ventriculomegaly Pos. Pos. IgG AF II Mother II
IgG avidity low IgM Infant II
IgA
6 29 IgG, IgM, IgA 28 Hydrocephaly IUD, 35 Pos. Pos. ND AF II Mother II
IgG avidity low Infant NA
7 28 IgG, IgM, IgA 27 Hydrocephaly Pos. Pos. IgG AF II Mother II
IgG avidity low NP Chorioretinitis IgM Infant NA
IgA
8 32 IgG, IgM, IgA 27 Hydrocephaly NP Pos. ND IgG AF II Mother NA
NP Choroidoretinitis IgM Infant NA
IgA
9 34 IgG, IgM, IgA 28 Ventriculomegaly Pos. ND IgG AF II Mother NA
IgG avidity low NP Chorioretinitis IgM Infant NA
IgA
10 28 IgG, IgM, IgA 28 Hydrocephaly ND ND IgG CSF NT Mother NA
IgG avidity low IgM Infant NA
IgA
11 13 IgG, IgM, IgA Asymptomatic Pos. Pos. IgG AF NT Mother II
IgG avidity low IgM Infant II
IgA
12 20 IgM Asymptomatic Pos. Pos. IgG AF NT Mother II
25 IgG, IgM, IgA IgM Infant II
IgG avidity low IgA
13 30 IgG, IgM, IgA Asymptomatic Pos. Pos. IgG AF NT Mother Uncertain
IgG avidity low IgM Infant Uncertain
IgA
14 28 IgG, IgM, IgA Asymptomatic Neg. Pos. IgG AF NT Mother Uncertain
IgG avidity low IgM Infant II
IgA
15 27 IgG, IgM, IgA Asymptomatic Pos. Neg. IgG AF NT Mother Atypical
IgG avidity low IgM Infant Atypical
IgA
16 30 IgG, IgM, IgA Asymptomatic ND ND IgG NB NT Mother NA
IgM Infant NA
IgA
17 15 IgG, IgM, IgA Asymptomatic ND ND IgG NB NT Mother Atypical
IgG avidity low IgM Infant Atypical
IgA
18 32 IgG, IgM, IgA 29 Hydrocephaly Pos. ND IgG NB NT Mother II
IgG avidity high IgM Infant II
IgA
19 31 IgG, IgM, IgA 31 Hydrocephaly NP ND ND IgG AF NT Mother II
IgG avidity low IgM Infant II
IgA
a Abbreviations: GW, gestational week; NP, neonatal period; IUD, intrauterine death; MI, mouse inoculation; NS, neonatal serology; pos., positive result; neg.,
negative; ND, not done; NT, nontypeable; NA, not available; NB, neonatal blood. Mothers’ serology results are given for the first available test. CSF was used for PCR
or mouse inoculation in cases 1 and 18 and AF was used in the remaining cases. Uncertain refers to low values with all peptides, such that a strain type could not be
reliably determined. Atypical refers to the reaction with peptides from different strain types, reflecting either mixed infection or possibly unusual genotypes. The tests
used and their cutoff values are given in the text.
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Sensitivity of multiplex PCR in amniotic fluid. To establish
the sensitivity of the multiplex PCR, 1-ml volumes of AF or CSF
samples from uninfected pregnancies were spiked with lysates of
T. gondii equivalent to 0.5 to 10 parasites per sample. Samples
were then directly processed for PCR. The sensitivity of detection
ranged from 2.5 to 10 parasites per sample in both AF (Fig. 1A)
and CSF (Fig. 1B). In the primary round of multiplex PCR (left
side of Fig. 1), no amplification products were seen, consistent
with the low input of parasites. In the second round, specific
products were detected for each marker (right side, Fig. 1). Dif-
ferences in the sensitivity of detection of individual markers likely
reflect efficiencies based on different PCR primers, since all of
these targets are present as a single copy per genome.
We also tested the sensitivity of multiplex PCR under con-
ditions that more closely approximate sample processing. In
this instance, defined numbers of whole parasite cells were
added to 1 ml of normal AF samples and centrifuged, and the
pellet was extracted and analyzed. Under these conditions, the
sensitivity was approximately 25 parasites per sample (data not
shown). The decreased sensitivity under these conditions likely
reflects inefficiency in recovery of parasites following centrifu-
gation and/or extraction. However, since these conditions
more closely simulate processing of clinical AF samples, they
likely reflect the real sensitivity of this method versus the more
efficient detection seen when small samples are spiked with
parasites and assayed directly.
Genotypes of T. gondii by multiplex PCR-RFLP analysis.
Nineteen cases of confirmed congenital toxoplasmosis were
examined here, as summarized in Table 1. In 14 cases, con-
genital toxoplasmosis was confirmed by two of the following
criteria: positive results by B1 PCR with AF or CSF; positive
serology in mice after inoculation of AF or CSF samples into
mice; and presence of specific IgM and/or IgA in the neonate
(Table 1). Four neonates were classified as congenitally in-
fected based solely on demonstration of specific IgG, IgM,
and/or IgA antibodies in repeated tests following birth (Table
1). In the remaining case, only IgG was demonstrated, how-
ever, it was included in the study based on inoculation of AF
into naı¨ve mice and their subsequent positive serology (case
number 14). Ventricular dilatation (ventriculomegaly or hy-
drocephalus) was detected prenatally in 11 cases (Table 1).
Five out of 11 symptomatic cases died, two in utero and three
in early postnatal periods. Chorioretinitis was diagnosed in
four neonates. Eight cases were asymptomatic.
For 14 of the cases, AF samples were used for detection of
parasite DNA by multiplex PCR (Table 1). However, for sev-
eral cases, only CSF (numbers 1 and 10), or only neonatal
blood (numbers 16, 17, and 18) was available. PCR amplifica-
tion of T. gondii genetic markers was only successful in 9 out of
19 samples; the remaining samples were negative in all tests
(Tables 1 and 2). Eight of the nine cases that were positive
were detected with AF samples and the remaining positive was
obtained from a CSF sample.
Gene-specific amplification products were subjected to re-
striction enzyme digestion to identify characteristic RFLPs and
the genotypes were determined based on the combination of
alleles at different markers (16). For eight of the nine samples,
the genotype was determined to be type II for all four markers
(Table 2). A representative example is shown for 3-SAG2 in
FIG. 1. Sensitivity of multiplex PCR analysis of T. gondii in AF (A) and CSF (B) samples. Multiplex PCR was performed for the four genetic
markers SAG2 (5 and 3 amplified separately), SAG3, GRA6, and BTUB followed by electrophoresis in agarose gels containing ethidium bromide.
Lanes 1, 6, and 7 are negative controls, and lanes 2 to 5 are samples spiked with 0.5, 2.5, 5.0, and 10.0 T. gondii cells, respectively.
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Fig. 2. In one CSF sample (number 1), genotype II was deter-
mined only for the 3-SAG2 and GRA6 markers and the sam-
ple was negative for the remaining markers (Table 2). Geno-
typing was not successful with the second CSF sample,
suggesting a lower parasite concentration in CSF than in AF.
In all three severe cases that were not successfully genotyped,
late referral complicated proper sampling and this may have
caused in the negative results.
Genotyping at the SAG1 locus and type X. The genotype at
SAG1 was also examined using gene-specific PCR to distin-
guish between parasite type II and newly described type X
(18). RFLP analysis does not discriminate between type X and
type II strains at the markers (SAG2, SAG3, and GRA6) used
here. However, type X can be distinguished from type II by the
presence of a type I RFLP pattern at SAG1 after digestion with
Sau961 (18). PCR-RFLP analysis of the nine clinical samples
studied here showed an RFLP pattern at SAG1 consistent with
type II and distinct from type X (Table 2).
Serological typing of clinical samples. Sera from both the
mother and infant were tested for reaction to allele-specific
peptides to define the genotype of parasites causing infection,
as described previously (17). A total of 28 mother and infant
sera from 15 different cases of congenital toxoplasmosis (two
were not available as paired samples) were provided to the
Toxoplasma Serology Laboratory (Palo Alto Medical Re-
search Foundation) as a blinded set of samples without any
identifying information about strain genotype, clinical disease,
or dye test titer prior to analysis. Sera were tested against a set
of polymorphic peptides that have previously been shown to
identify strain-specific antibodies present in patient serum
(17). Reaction to these peptides can thus be used to genotype
the strain responsible for infection.
Positive control sera (Table 3) established that the assay was
reproducible and working within the detection and cutoff limits
as previously established by Kong and colleagues (17). The
results show that 20 of 28 sera (representing 12 of 15 cases)
produced a reactivity pattern consistent with infection by type
II strains (positive reaction with one or more type II peptides
designated 6II, 6 d-II, 7 II, and 7 d-II) (Table 3). Two sera
(maternal sera from cases 2 and 14 in Table 1) gave no clear
indication of the type responsible for infection, as reactivity
against all peptides was weak. However, in both cases, sera
from the infant showed reactivity to at least one type II pep-
tide. These results for maternal and infant sera were consis-
tently observed in repeated assays.
IgG antibodies detected in neonatal sera are almost cer-
tainly derived from transfer of maternal antibodies. Thus, the
negative results for the mothers of these infants is likely due to
degradation of the sample during storage. Paired maternal and
infant sera from case number 13 reacted weakly with the 6
d-I/III peptide but none of the other I/III diagnostic peptides.
All type I/III infection sera previously characterized have
shown strong reactivity with peptide 6 I/III, so lack of reactivity
with this peptide precludes assigning these two sera. Paired
maternal and infant sera from case 15 and case 17 reacted
strongly with both type II and type I/III peptides, suggesting a
possible mixed infection. Mixed infections are highly unusual,
and thus their reactivity is listed as atypical. Based on the
serological testing, it was concluded that 12 of the 19 cases of
congenital toxoplasmosis were due to type II strains.
FIG. 2. RFLP analysis of PCR products amplified from AF and
CSF samples from cases of congenital toxoplasmosis. 3-SAG2 ampli-
fication products digested with HhaI were resolved in 3% agarose gels
stained with ethidium bromide. The samples loaded in lanes I, II, and
III are representative of T. gondii strain types I, II, and III, respectively.
Samples from pregnancies with congenitally infected fetuses were
loaded in lanes 1 to 9. Genotyping revealed all nine positive samples
were type II strains of T. gondii. AF samples from uninfected pregnant
women (neg) served as negative controls.
TABLE 2. Genotypes of T. gondii in clinical samples from congenitally infected fetuses and newborns based on multiplex PCRa
Marker Restrictionenzyme









(10 ml) 7 8 9
5-SAG2 Sau3AI Negb Neg 1 1 1 1 1 1 1 1 1
3-SAG2 HhaI Neg 2 2 2 2 2 2 2 2 2 2
SAG3 NciI Neg Neg 2 2 2 2 2 2 2 2 2
GRA6 MseI 2 2 2 2 2 2 Neg 2 2 2 2
BTUB TaqI Neg Neg 2 2 2 2 2 2 2 2 2
BspEI Neg Neg 2 2 2 2 2 2 2 2 2
SAG1 Sau96I Neg Neg 2 2 2 2 2 2 2 2 2
HaeII Neg Neg 2 2 2 2 2 2 2 2 2
T. gondii
genotype
II II II II II II II II II
a Alleles are defined in reference 16. Genotype II is the result of allele 1 at 5-SAG2 and allele 2 at 3-SAG2.
b Neg, negative.
c Where sample type and volume are not specified for the case, the sample was 1 ml of AF.
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We used multiplex PCR to genotype strains of T. gondii
directly in AF and CSF samples from complicated congenital
infections in Poland. We found exclusively type II strains of T.
gondii and eight of nine typeable cases represented severe
cases of toxoplasmosis. Serological typing was consistent with
type II genotypes causing the majority of symptomatic and
asymptomatic infections. Our findings indicate that type II
strains can cause both benign and complicated cases and are
consistent with the hypothesis that the severity of infection is
primarily related to the burden of parasites.
T. gondii has a highly clonal population structure and most
human infections are caused by one of three main genotypes.
Type II strains cause the majority (70 to 80%) of human cases
of toxoplasmosis reported previously from North America and
Europe (primarily France) (1, 5, 12–14). Type I is infrequent in
nature, but has been shown to be more common both in con-
genital toxoplasmosis (6) and in AIDS patients (14). Type III
strains are largely found in animals and only rarely cause hu-
man infection for reasons that are unknown (14).
In the present study, all of the cases typeable by nested PCR
were type II, and eight of nine positives were obtained from




1 (6 I/III) 2 (6 d-I/III) 3 (6 II) 4 (6 d-II) 5 (7 II) 6 (7 d-II) 7 (7 III) 8 (7 d-III)
Negative control 1.0 1.0 1.0 1.0 1.1 1.2 1.0 1.0
Positive type II control 1.2 1.0 4.1 1.6 9.1 1.1 1.0 1.1
Positive type II control 1.2 1.0 4.2 1.6 9.1 1.1 1.1 1.1
Positive type I/III control 2.4 1.0 1.1 1.1 1.4 1.1 1.1 1.1
Positive type I/III control 2.4 1.0 1.1 1.1 1.4 1.1 1.1 1.1
1 Mother 1.1 1.0 2.0 1.2 16.7 1.0 1.0 1.1 II
Infant 1.3 1.0 1.3 0.9 2.0 1.0 0.9 1.0 II
2 Mother 1.0 1.0 1.0 0.9 1.3 1.0 1.0 1.0 Uncertain
Infant 1.0 1.0 1.1 1.0 1.6 1.0 1.0 1.0 II
3 Mother 1.0 1.7 5.5 4.8 3.5 1.1 1.1 1.2 II
Infant 1.0 1.4 4.9 4.0 2.8 1.3 1.0 1.1 II
4 Mother 1.1 0.9 2.4 1.7 4.5 1.1 1.1 1.1 II
Infant 1.1 1.0 1.7 1.4 2.4 1.0 1.1 1.1 II
5 Mother 1.0 1.0 1.4 1.1 2.6 1.0 1.0 1.0 II
Infant 1.0 1.0 2.3 1.1 3.8 1.1 1.3 1.1 II
6 Mother 1.3 1.0 2.4 1.0 7.6 1.0 1.1 1.1 II
7 Mother 1.1 1.0 2.3 2.0 4.6 1.3 1.1 1.0 II
11 Mother 1.0 1.1 1.4 1.4 8.1 1.1 1.1 1.1 II
Infant 1.0 1.0 1.4 1.3 6.1 1.0 1.0 1.1 II
12 Mother 1.1 1.0 1.0 1.0 1.9 1.1 1.0 1.1 II
Infant 1.0 1.0 1.2 1.1 4.3 1.0 1.0 1.0 II
13 Mother 1.1 1.6 1.1 1.1 1.3 0.9 1.0 1.0 Uncertain
Infant 1.0 1.5 1.1 1.1 1.2 1.0 1.0 1.0 Uncertain
14 Mother 1.4 1.1 1.0 1.0 1.1 1.0 1.0 1.0 Uncertain
Infant 1.0 1.1 1.1 1.2 2.5 1.2 1.1 1.1 II
15 Mother 12.5 1.7 1.1 1.4 3.3 1.2 2.8 2.2 Atypical
Infant 9.7 1.2 1.0 1.0 2.0 1.1 2.3 1.9 Atypical
17 Mother 4.9 1.2 7.9 9.6 Off scale 1.0 3.2 2.6 Atypical
Infant 3.5 1.0 5.8 2.5 12.0 1.0 2.5 2.2 Atypical
19 Mother 1.0 1.0 3.2 2.0 7.9 1.0 1.0 1.0 II
Infant 1.1 1.0 1.6 1.0 6.4 1.0 1.0 1.0 II
a Peptides utilized in testing are listed across the top of the table. The negative control value is the mean for two negative peptides (see text). Positive controls were
provided by patient sera from previously typed cases of toxoplasmosis (see text). Results are shown for sera from the cases listed in Table 1. Sera were reacted against
the panel of eight strain-specific peptides to identify allele-specific antibodies present in infection serum. All data were normalized by dividing the A405 reading for each
serotyping peptide against the mean of the two control peptides. Values of 1.4 were considered significant (17). Uncertain refers to low values with all peptides, such
that a strain type could not be reliably determined. Atypical refers to reaction with peptides from different strain types, reflecting either mixed infection or possibly
unusual genotypes.
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severe cases. Five cases resulted in death in utero or early in
the neonatal period. A total of 14 of 19 cases studied in the
present report were found to be due to type II strains, based on
genotyping and/or serological typing. The samples studied here
come from a referral hospital that receives patients with com-
plicated pregnancies from a wide area of Poland. Thus, our
studies provide a baseline for further analysis of congenital
cases of toxoplasmosis in Poland to determine if this pattern of
type II infections is widespread. Ajzenberg et al. also described
type II in eight out of eight cases of fetal or newborn death and
in a majority (73 of 86 samples) of all congenital cases studied
from France (1). In contrast to these findings, a study from
Spain based on single-locus PCR-RFLP analysis reported that
non-type II strains were found in 12 of 13 congenital infections
(6). This difference may be primarily related to geography,
since any referral bias for severe cases would appear to be the
same in both studies. Collectively, these results indicate mul-
tiple strain types can be associated with severe toxoplasmosis
due to congenital infection.
Clinical forms of congenital toxoplasmosis vary widely. Only
5 to 10% of all infected fetuses develop serious disease, and the
majority of infections are asymptomatic (23). Chorioretinitis
can result from both congenital and acquired infection (11).
Human ocular toxoplasmosis is associated with different
strains, including strains containing a mixture of type I and
type III genotypes (9). Chorioretinitis was diagnosed in four
neonates presented in our study, all due to type II infections.
Recently, Miller et al. described T. gondii genotype X that was
associated with brain lesions and mortality in sea otters in the
western United States (18). Our samples from cases with se-
vere clinical signs of the disease (hydrocephalus and fetal/
neonatal death) were found to match the type II, not the type
X, genotype.
Semiquantitative PCR with the B1 gene has been used pre-
viously to estimate the parasite burden in AF during congenital
infection (10, 24). The parasite load estimated using real-time
PCR was less then 10 parasites/ml in 40 to 46% of AF samples
and 11 to 100 parasites/ml in 30 to 40% of samples (4, 24)
Previous studies using real-time PCR in AF established the
relationship between high parasite burden and severity of dis-
ease (24). PCR detection with B1 is more sensitive than the
methods used here; however, it is not sufficiently polymorphic
to allow simple RFLP typing of alleles. For these reasons, we
developed nested PCR-RFLP typing of several single-copy
genes that are polymorphic (16). While these markers are well
suited for typing, they are less sensitive overall than detection
methods based on B1 PCR.
In our study, the sensitivity of parasite detection by multiplex
nested PCR was 25 parasites/ml in AF and CSF. Thus, the
negative status of many of our samples may have resulted from
small amounts of parasite DNA in these samples. Consistent
with this, most of those strains that were typeable by PCR (25
parasites/ml) were from severe cases. These findings are con-
sistent with an association between parasite burden and dis-
ease association established previously by more quantitative
methods (10, 24). The failure to type some cases by nested
PCR-RFLP analyses also raises the possibility that the present
samples have an inherent bias. However, our conclusion that
type II strains cause the majority of infections in this sample
group is supported by similar results obtained by serological
testing, which also identified five additional cases of type II
infections that were only typeable by serology. The failure to
detect type I/III samples among these samples is not due to
assay bias, since both PCR-based and serological typing per-
form well with standards that included samples from patients
with infections of known genotypes in the case of serology
(Table 3).
Severe symptoms of congenital toxoplasmosis occur
mostly as a result of infections that occur early in pregnancy.
Results of real-time PCR showed that severe outcome was
associated with high parasite load and the highest parasite
concentrations were found when seroconversion occurred
early in pregnancy (24). In our study, the timing of the
mother’s primary infection was uncertain due to the lack of
serological monitoring. However, all of the mothers had
serological results suggesting primary infection during the
first or second trimester of pregnancy (IgM and/or IgA
and/or low IgG avidity). In Poland, serological screening in
pregnancy is not routinely performed, although anti-T. gon-
dii testing is recommended. Routine ultrasound screening
during pregnancy is well established in Poland.
In our study, detection of symptoms in a fetus was typically
followed by prenatal diagnosis of congenital toxoplasmosis.
The prevalence of T. gondii (41.3% seropositive) in pregnant
women in Poland is high (20, 20a), and screening of cord blood
from neonates, which per se does not detect all congenitally
infected cases, indicates a frequency of infection of	1 in 1,000
to 2,000 live births (21, 22). Most of these cases are likely not
severe, and the high rate of fetal defects among the cases
studied here is mainly due to the referral of complicated preg-
nancies to RIPMMH, suggesting that the majority of asymp-
tomatic cases are not detected. Elective interruption of preg-
nancies in Poland is very rare, so the emphasis is placed on
possible treatment in utero and postnatally (19).
Strain type has been suggested to play a role in determining
the outcome of T. gondii infection (3). In our study, T. gondii
type II was identified in eight AF and one CSF sample from
Polish fetuses and neonates with severe forms of disease. Im-
portantly, for all samples for which PCR genotype data were
available, the serotyping assay accurately predicted infection
by a type II strain (Tables 2 and 3). While most asymptomatic
cases were generally not typeable by PCR, serological analysis
indicated a majority of these were also type II. The reaction
between mothers and infants was highly correlated, likely re-
flecting the fact that this assay detects IgG that is acquired by
the infant by transfer across the placental barrier in utero.
Serum from several cases (13 and 15) reacted to peptides of
both type II and I/III, raising the possibility that these patients
were multiply infected either with a mix of different strains or
by a novel strain(s) that possesses alleles at GRA6 and GRA7
that induce antibodies that react to peptides of both alleles.
Interpretation of these sera would require parasite genotype
information, but unfortunately, insufficient parasite DNA was
recovered from these patients to allow PCR-RFLP genotyping.
Our findings demonstrate that type II strains can be associated
with either mild and severe disease and support the hypothesis
that high parasite concentration is primarily responsible for the
severity of congenital disease. They also demonstrate a close
concordance of parasite genotyping by PCR-based genetic mark-
ers and serological testing using strain-specific epitopes. Ex-
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panded use of serological typing should enable more comprehen-
sive analysis of the contribution of parasite genotype to clinical
severity of toxoplasmosis.
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